Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

SKLB1002

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Ocular angiogenesis is a major cause of severe vision loss, which can affect several parts of the eye, including the retina… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
BackgroundRecent studies suggested that cancer stem-like cells contribute to tumor vasculogenesis by differentiating into… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2017
2017
Aims/hypothesisDiabetes promotes cerebral neovascularisation via increased vascular endothelial growth factor (VEGF) angiogenic… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2013
2013
Psoriasis is a common chronic inflammatory skin disease and its underlying pathogenesis is still not fully understood… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2012
2012
Vascular endothelial growth factor receptor (VEGFR) or vascular endothelial growth factor (VEGF) inhibitors have shown only… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
A de novo VEGFR2-inhibited compound SKLB1002 which is independently developed in our laboratory has been described for… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2011
Highly Cited
2011
Purpose: VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis agents, have been applied in the cancer treatment… Expand
  • figure 1
  • figure 2
  • figure 2
  • figure 3
  • figure 4
2011
2011
Purpose: VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis agents, have been applied in the cancer treatment… Expand
  • figure 1
  • figure 2
  • figure 2
  • figure 3
  • figure 4